Synapse - Advanced Practice Providers

Results (37)

Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
Blood (2022)

Fulltext@MSK | Save

Utility of routine pulmonary function test after autologous hematopoietic cell transplantation in lymphoma

Meeting Abstract

Dahi, P. B.; Geyer, A.; Kenny, S.; Flynn, J.; Devlin, S. M.; Ruiz, J. D.; Lahoud, O. B.; Matasar, M. J.; Moskowitz, C. H.; Perales, M. A.; more...
Transplantation and Cellular Therapy (2022)

Fulltext@MSK | Save

Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: A single-center experience

Journal Article

Pak, T. K.; Dixon, B. N.; Buege, M. J.; Dao, P. H.; Leary, M. H.; Jarrett, J. C.; Duggan, T. A.; Caron, P.; Falchi, L.; Hamlin, P.; more...
Leukemia and Lymphoma (2022)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence

Meeting Abstract

Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
Blood (2021)

Fulltext@MSK | Save

Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)

Meeting Abstract

Kumar, A.; Soumerai, J. D.; Abramson, J. S.; Batlevi, C. L.; Chadha, P.; Dogan, A.; Falchi, L.; Flaherty, K.; Friedman, C.; Grieve, C.; more...
Blood (2021)

Fulltext@MSK | Save

Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Journal Article

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial

Journal Article

Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
The Lancet Haematology (2021)

Fulltext@MSK | Save

Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts

Journal Article

Mehta-Shah, N.; Lunning, M. A.; Moskowitz, A. J.; Boruchov, A. M.; Ruan, J.; Lynch, P.; Hamlin, P. A.; Leonard, J.; Matasar, M. J.; Myskowski, P. L.; more...
American Journal of Hematology (2021)

Fulltext@MSK | Save

Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma

Meeting Abstract

Kumar, A.; Batlevi, C.; Drullinsky, P.; Grieve, C.; Laraque, L.; Joseph, A.; Mahajan, N.; Matasar, M.; Straus, D.; Zelenetz, A.; more...
Hematological Oncology (2021)

Fulltext@MSK | Save

Noninvasive monitoring of mantle cell lymphoma by immunoglobulin gene next-generation sequencing in a phase 2 study of sequential chemoradioimmunotherapy followed by autologous stem-cell rescue

Journal Article

Kumar, A.; Bantilan, K. S.; Jacob, A. P.; Park, A.; Schoninger, S. F.; Sauter, C.; Ulaner, G. A.; Casulo, C.; Faham, M.; Kong, K. A.; more...
Clinical Lymphoma, Myeloma and Leukemia (2021)

Fulltext@MSK | Save